drugset / Trial / NCT04583813
Empagliflozin and Atrial Fibrillation Treatment
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, in patients with diabetes mellitus or overweight, heart failure and atrial fibrillation.
Timeline
- Start
- 2021-09
- Primary completion
- 2024-01
- Completion
- 2024-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Empagliflozin | Small molecule | 10 mg | Oral |